Abstract
Objective
Many patients with heart failure (HF) do not receive recommended treatments , resulting in suboptimal outcomes. We aimed to investigate the impact of implementing recommended HF therapies on health outcomes, and the costs and effectiveness of interventions for improving adherence.
Methods
The health benefits of ACE inhibitor (ACEi), beta-blockers and optimal therapy (ACEi and beta-blockers if not contraindicated) following hospitalisation for HF were combined with evidence on uptake. The aim was to examine how much health was lost as a result of failure to follow guidelines, and how much could be gained using strategies to promote uptake.
The net health benefits of different treatments (measured in quality-adjusted life-years (QALYs)) were estimated using a decision analytic model and treatment effectiveness from the literature. Data on the number of patients who would have benefitted from the additional treatments was estimated from 2010 to 2013 using the National Heart Failure Audit.
Results
Each recommended treatment was associated with positive net health benefit. In 2010, 4019 (38.3% of) patients would have benefitted from additional treatments rising to 4,886 patients in 2013 (although falling to 25.2% of patients). Failure to follow guidelines resulted in large health losses. In 2010, if all patients had received optimal therapy, 1,569 QALYs would have been gained, implying a maximum justifiable investment in interventions to promote uptake of £31.4 million.
Conclusion
Current gaps in translation of evidence to practice in hospitals are associated with significant health losses. Strategies to encourage uptake of guidelines could be effective and cost effective.
Many patients with heart failure (HF) do not receive recommended treatments , resulting in suboptimal outcomes. We aimed to investigate the impact of implementing recommended HF therapies on health outcomes, and the costs and effectiveness of interventions for improving adherence.
Methods
The health benefits of ACE inhibitor (ACEi), beta-blockers and optimal therapy (ACEi and beta-blockers if not contraindicated) following hospitalisation for HF were combined with evidence on uptake. The aim was to examine how much health was lost as a result of failure to follow guidelines, and how much could be gained using strategies to promote uptake.
The net health benefits of different treatments (measured in quality-adjusted life-years (QALYs)) were estimated using a decision analytic model and treatment effectiveness from the literature. Data on the number of patients who would have benefitted from the additional treatments was estimated from 2010 to 2013 using the National Heart Failure Audit.
Results
Each recommended treatment was associated with positive net health benefit. In 2010, 4019 (38.3% of) patients would have benefitted from additional treatments rising to 4,886 patients in 2013 (although falling to 25.2% of patients). Failure to follow guidelines resulted in large health losses. In 2010, if all patients had received optimal therapy, 1,569 QALYs would have been gained, implying a maximum justifiable investment in interventions to promote uptake of £31.4 million.
Conclusion
Current gaps in translation of evidence to practice in hospitals are associated with significant health losses. Strategies to encourage uptake of guidelines could be effective and cost effective.
| Original language | English |
|---|---|
| Article number | e000726 |
| Number of pages | 8 |
| Journal | Open Heart |
| DOIs | |
| Publication status | Published - 22 Dec 2017 |